Scientific Agenda

Wednesday, 27 June, 2012

12:30

Expert discussion (by invitation only): Metastatic pancreatic cancer Scientific committee and selected experts

Session I: Selected abstracts I

Chairs: Mario Dicato, MD and Eric Van Cutsem, MD, PhD

15:00

Welcome and introduction
Congress Chairs Mario Dicato, MD and Eric Van Cutsem, MD, PhD

15:05

Presentation of selected abstracts

International Experts' Consensus for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer
F. Bonnetain, et al., O-0001

A Phase2 adjuvant trial of GI-4000 plus gemcitabine vs. gemcitabine alone in Ras + patients with resected pancreas cancer: R1 subgroup analysis
D. Richards, et al., O-0002

Phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) combined with gemcitabine (Gem) in advanced pancreatic cancer (APC)
E. Mitchell, et al., O-0003

Updated analysis of phase II study of the anti-IGF-1R antibody MK-0646 with gemcitabine +/- erlotinib for advanced pancreatic cancer (APC)
R. Shroff, et al., O-0004

FOLFIRI.3 alternating with gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma: The randomized multicenter AGEO phase II trial FIRGEM
I. Trouilloud, et al., O-0005

Session II: Cancer of the pancreas and bile ducts

Chairs: Jordan D. Berlin, MD and Mario Dicato, MD

16:00

How to improve surgical results for pancreatic cancer?
Markus W. Büechler, MD

16:20

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Manuel Hidalgo, MD, PhD

16:40

Why is pancreatic cancer so thrombogenic?
Mario Dicato, MD

17:00

How can a borderline resectable or non-resectable pancreatic cancer become resectable? Chemo or chemoradiotherapy?
Jordan D. Berlin, MD

17:20

Presentation of selected abstracts

Dose escalation to rash for erlotinib plus gemcitabine in patients with metastatic pancreatic cancer: The phase II RACHEL (BO21128) study
E. Van Cutsem, et al., O-0006

Exploratory serum biomarker analyses from BO21129, a phase II study of erlotinib in second-line pancreatic cancer: Potential role of amphiregulin
M. Ducreux, et al., O-0007

Randomized phase II study of gemcitabine + TH-302 vs gemcitabine in previously untreated patients with unresectable locally advanced and metastatic pancreatic cancer (PAC)
D. Ryan, et al., O-0008

17:50

Debate: This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma

Pro
Marc Ychou, MD, PhD

Contra
Margaret A. Tempero, MD

18:20

New agents in pancreatic cancer
Eileen M. O’Reilly, MD

18:40

Should patients with resected bile duct cancer receive an adjuvant treatment?
Juan W. Valle, MD

19:00

Adjourn

CLOSED SESSION (by invitation only)

Parallel with Session II: Cancer of the pancreas and bile ducts

16:00

Strategy of national and international clinical trial groups

19:00

Adjourn closed session

Thursday, 28 June 2012

CLOSED SESSION (by invitation only)

Parallel with Session III: Meet the expert concurrent presentations and Session IV: Cancer of the liver

8:00

How to go forward with translational research in GI Cancer

Session III: Meet the expert concurrent presentations

8:00

Anal cancer
Robert Glynne-Jones, MBBS, FRCR, FRCP and Karin Haustermans, MD, PhD

Cholangiocarcinoma and gall bladder cancer
Juan W. Valle, MD

Supportive cancer: Management of anemia and emesis – guidelines
Mario Dicato, MD

GIST
John R. Zalcberg, MD, PhD, FRACP

Surgical topic
Speaker invited

Medical writing
Daniel G. Haller, MD

9:00

Session adjourns

Session IV: Cancer of the liver

Chairs: Jordi Bruix, MD, PhD and Wolff Schmiegel, MD, PhD

9:00

Presentation of selected abstract

Second line therapy in hepatocellular carcinoma (HCC): A randomized controlled phase 2 trial (RCT) with tivantinib (ARQ 197)
C. Porta, et al., O-0009

9:10

Pathologic and molecular changes occurring in HCC
Josep M. Llovet, MD

9:30

Is a biopsy in a liver nodule/HCC always needed before starting a treatment?
Jordi Bruix, MD

9:45

How to decide in the jungle of local/regional therapies for HCC?
Chris Verslype, MD, PhD

10:05

New agents on the horizon in HCC
Ghassan K. Abou-Alfa, MD

10:20

Keynote lecture 1: Genetic screening for colorectal cancer: For whom and how? Judith Balmaña, MD

10:50

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session V: Rare tumors: Neuroendocrine tumors and gastrointestinal stromal tumors

Chairs: Roberto Labianca, MD and John R. Zalcberg, MD, PhD, FRACP

11:20

Whom to treat and how long to treat after resection of GIST
John R. Zalcberg, MD, PhD, FRACP

11:35

What should a pathologist report in a NET?
Aurel Perren, MD

11:55

Medical treatment of NET: Somatostatin anologues, biological and/or chemotherapy
Martyn E. Caplin, BSc Hons, DM, FRCP

12:15

Efficacy and toxicity of peptide receptor targeted radiopeptide therapy
Martin A. Walter, MD

12:35

Presentation of selected abstract Poorly differentiated neuroendocrine carcinomas of the pancreas: Is survival really poor in the long-term follow-up?
G. Barugola, et al., O-0010

12:45

Session adjourns

13:00

Concurrent luncheon symposia begin

14:30

Concurrent luncheon symposia adjourn

Session VI: Esophageal cancer

Chairs: Arnaud D. Roth, MD and Thomas Seufferlein, MD, PhD

14:45

Treatment of Barrett’s esophagus: Update on new endoscopic modalities
Ralf Kiesslich, MD, PhD

15:05

Is surgery alone still an option in esophageal cancer? For whom?
Christophe Mariette, MD, PhD

15:20

Debate: Which neoadjuvant treatment in GEJ?

Pro chemotherapy
Philippe Rougier, MD, PhD

Pro chemoradiotherapy
Karin Haustermans, MD, PhD

15:50

Tumor board: Discussion and cases
Karin Haustermans, MD, PhD and Philippe Rougier, MD, PhD

16:10

Travel Grant Award Ceremony

16:15

Break and poster viewing
Abstracts to be presented: Clinical/basic non-CRC abstracts

Session VII: Gastric cancer

Chairs: Andrés Cervantes, MD, PhD and Jin Li, MD, PhD

16:45

Carcinogenesis in gastric cancer
Fatima Carneiro, MD, PhD

17:05

How important is experience/volume in gastric cancer surgery?
Cornelis J. H. van de Velde, MD, PhD

17:25

Is a laparoscopy part of the initial staging?
Cornelis J. H. van de Velde, MD, PhD

17:35

Should all patients be treated with adjuvant and/or neoadjuvant treatment?
Arnaud D. Roth, MD

17:50

What is the reference cytotoxic regimen in advanced gastric cancer?
Florian Lordick, MD, PhD

18:05

Presentation of selected abstracts

Evaluation of MET-pathway biomarkers in a phase 2 study of rilotumumab plus epirubicin, cisplatin, and capecitabine in gastric/esophagogastric junction cancer
K. Oliner, et al., O-0011

Prognostic factors of overall survival (OS) in previously treated advanced gastric cancer (AGC): Analysis of the Phase 3 GRANITE-1 Trial
E. Van Cutsem, et al., O-0012

18:25

Targeted agents in gastric cancer
Speaker invited

18:45

Are all gastric cancers identical?
Manish A. Shah, MD

19:00

Session adjourns

19:15

Exclusive evening symposium begins

20:45

Exclusive evening symposium adjourns

Friday, 29 June 2012

Session VIII: Meet the expert concurrent presentations

Parallel with Session IX: Screening and prevention for GI cancer – ESDO symposium, Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer, and Session XI: Presentation of selected abstracts

8:00

Peritoneal metastases
Santiago González-Moreno, MD, PhD

Carcinoma of unknown origin
Nicholas A. Pavlidis, MD, PhD, FRCP

Treatment of elderly patients with GI cancer
Demetris Papamichael, MB, BS, FRCP

ESSO session on surgery: Liver resection and ablation techniques
Graeme J. Poston, MD and René Adam, MD

9:00

Session adjourns

Session IX: Screening and prevention for GI cancer – ESDO symposium

Parallel with Session VIII: Meet the expert concurrent presentations, Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer, and Session XI: Presentation of selected abstracts

Chairs: Nadir Arber, MD, MSc, MHA and Thomas Seufferlein, MD, PhD

8:00

Screening for colon cancer
Wolff Schmiegel, MD, PhD

Helicobacter Pylori and gastric cancer
Speaker invited

Chemoprevention for GI cancer
Nadir Arber, MD, MSc, MHA

9:30

Session adjourns

Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX: Screening and prevention for GI cancer – ESDO symposium, and Session XI: Presentation of selected abstracts

Chairs: Fortunato Ciardiello, MD, PhD and Alberto Sobrero, MD

8:00

Is DFS, RR or survival the best endpoint in colorectal cancer?
Marc Buyse, ScD

Which difference should we target?
Alberto Sobrero, MD

Pharmacodynamic endpoints
Fortunato Ciardiello, MD, PhD

Discussion

9:30

Session adjourns

Session XI: Selected abstracts II

Parallel with Session VIII: Meet the expert concurrent presentations, Session IX: Screening and prevention for GI cancer – ESDO symposium, and Session X: Clinical trials for GI oncologists – Trials and endpoints in GI cancer

Chairs: Michel Ducreux, MD, PhD and John L. Marshall, MD

8:00

Presentation of selected abstracts Improved early prediction of individual prognosis for patients with metastatic colorectal cancer: Joint modeling of tumor shrinkage with volume data
V. Heinemann, et al., O-0013

Effect of post-protocol anti-EGFR mAb therapy on survival outcomes in patients with wild-type KRAS mCRC treated with panitumumab plus chemotherapy
J.Y. Douillard, et al., O-0014

Survival according to prognostic risk factors in patients receiving first-line chemotherapy plus cetuximab in the CRYSTAL and OPUS studies
C.H. Köhne, et al., O-0015

Cetuximab combined with infusional 5-fluorouracil/folinic acid and oxaliplatin in metastatic colorectal cancer: Pooled analysis of COIN and OPUS study data
J. Taïeb, et al., O-0016

Randomized phase II study evaluating UFOX plus cetuximab versus FOLFOX4 plus cetuximab as first-line therapy in metastatic colorectal cancer: FUTURE
J.Y. Douillard, et al., O-0017

Efficacy and safety of bevacizumab in metastatic colorectal cancer: Overall and subgroup analyses of pooled data from randomized controlled trials
H. Hurwitz, et al., O-0018

Session XII: Special EONS nurses’ symposium: Management of patients with rectal cancer

Parallel with Session XIII: ESMO session: Focus on young medical oncologist

Chair: Lena Sharp, RN, PhD

9:00

Professional communication for increased patient safety in cancer care
Lena Sharp, RN, PhD

9:25

Management of toxicities: The patient experience after surgery and combination radio/chemotherapy
Speaker invited

9:50

Long-term effects of surgery and radiotherapy for colorectal cancer and quality of life
Speaker invited

10:15

Discussion

10:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XIII: ESMO session: Focus on young medical oncologist

Parallel with Session XII: Special EONS nurses’ symposium: Management of patients with rectal cancer

Chair: Roberto Labianca, MD

9:00

Novel predictive factors for patients treated with anti-angiogenetic drugs
Fotios Loupakis, MD, PhD

9:20

Status of the art of predictive factors for anti-EGFR drugs
Speaker invited

9:40

Prognostic/predictive factors in adjuvant treatment of colon cancer
Speaker invited

10:00

Keynote lecture 2: Should we take aspirin and/or prescribe it to our patients?
Timothy Bishop, MD

10:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XIV: Multimodality therapy for rectal cancer

Chairs: Karin Haustermans, MD, PhD and Bernard Nordlinger, MD

11:00

Imaging in rectal cancer: What is mandatory for optimal staging?
Gina Brown, MD

11:20

Organ sparing-surgery in rectal cancer: How important is it? How can we progress with it?
Andre D’Hoore, MD, PhD

11:35

Is local excision by TEMS adequate treatment for early rectal cancer?
Chris Cunningham, MD

11:50

Which neoadjuvant treatment in rectal cancer?
Robert Glynne-Jones, MBBS, FRCR, FRCP

12:10

A glimpse into the future of new radiation techniques for rectal cancer
Speaker invited

12:25

Do we need post-operative chemotherapy in patients with pathologic CR to neoadjuvant therapy?
Philippe Rougier, MD, PhD

12:40

Presentation of selected abstracts

Severe fluoropyrimidines toxicities: A simple and effective way to avoid them. Screen effectively for DPD deficiencies
M. Boisdron-Celle, et al., O-0019

Personalized treatment planning of stage II and IIIA colon cancer patients using genomic classifiers (ColoPrint/ MSI-Print)
R. Salazar, et al., O-0025

13:00

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

Session XV: Highlights in cancer

Chairs: Nadir Arber, MD, MSc, MHA

15:00

Keynote lecture 3: Gastric cancer surgery in Japan: Why is it different?
Takeshi Sano, MD

15:30

Keynote lecture 4: What can we afford: Health economics in GI cancer
John L. Marshall, MD

16:00

Keynote lecture 5: Priorities for clinical research in GI cancer
Daniel G. Haller, MD

16:30

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Session XVI: Hot topics in colon cancer

Chair: Salvatore Siena, MD

17:00

Are we making progress in the molecular taxonomy of colon cancer?
Sabine Tejpar, MD, PhD

17:20

Should MSI be determined in all patients with stage II and III colon cancer patients?
Ramon Salazar, MD

17:35

Is gene signature based selection ready for clinical use?
Pierre Laurent-Puig, MD, PhD

17:50

Presentation of selected abstract

18:00

How to treat a patient with stage III colon cancer in 2012
Thierry André, MD

18:20

Are all KRAS mutations identical?
Salvatore Siena, MD

Session XVII: Poster discussion session

18:40

Poster discussion session I on colon cancer (PD-0001 to PD-0009)
Thomas Grüenberger, MD

18:50

Poster discussion session II on colon cancer (PD-0010 to PD-0014)
Speaker invited

19:00

Poster discussion session III on colon cancer (PD-0015 to PD-0025, PD-0034)
Speaker invited

19:10

Poster discussion on non-colorectal cancer (PD-0026 to PD-0032, PD-0035)
Jin Li, MD, PhD

19:20

Session adjourns

Saturday, 30 June 2012

Session XVIII: ESMO Consensus Conference: Interactive Session on Colorectal Cancer Guidelines

Chairs: Hans-Joachim Schmoll, MD, PhD and Andrés Cervantes, MD, PhD

8:30

Introduction to ESMO consensus conference - Why do we need guidelines?
Andrés Cervantes, MD, PhD

8:45

A clinical case presentation on localized rectal cancer
Noelia Tarazona Llavero, MD

8:55

Discussant
Vicenzo Valentini, MD

9:10

A clinical case presentation on advanced colon cancer (first and second line therapy)
Alexander Stein, MD

9:25

Discussants
Hans-Joachim Schmoll, MD, PhD and Andrés Cervantes, MD, PhD

9:40

Break

Session XIX: Metastatic colorectal cancer

Chairs: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD

10:10

What is the best cytotoxic backbone for biologicals?
Jean-Yves Douillard, MD, PhD

10:30

Which biological targeted agent and for whom?
Michel Ducreux, MD, PhD

10:50

Maintenance treatment or stop and go: What is the standard?
Aimery de Gramont, MD, PhD

11:00

Presentation of selected abstracts

Bevacizumab + chemotherapy beyond first progression in metastatic colorectal cancer patients previously treated with bevacizumab-based therapy: TML study subgroup findings
T. André, et al., O-0020

Randomised phase III study of bevacizumab + chemotherapy beyond progression in bevacizumab-treated patients with metastatic colorectal cancer: TML study KRAS subgroup findings
E. Van Cutsem, et al., O-0021

11:20

Molecular markers beyond KRAS for anti-EGFR targeted agents and markers for angiogenesis inhibitors – What is new?
Heinz-Josef Lenz, MD

11:35

Presentation of selected abstracts

X-PECT study results: A phase III randomized study of perifosine plus capecitabine vs. placebo plus capecitabine in refractory mCRC patients
J. Bendell, et al., O-0022

Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)
A. Sobrero, et al., O-0023

Phase 2 randomized, noncomparative, open-label study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM)
C. Pericay, et al., O-0024

12:05

New drugs on the horizon for CRC in 2012
Eric Van Cutsem, MD, PhD

12:25

New targets in gastrointestinal cancer
Josep Tabernero, MD, PhD

12:45

Session adjourns

13:00

Concurrent luncheon symposia and ESO Cancer Observatory begin

14:30

Concurrent luncheon symposia and ESO Cancer Observatory adjourn

Session XX: Surgery and peritoneal and liver metastases

Chairs: Mario Dicato, MD and Graeme J. Poston, MD

14:45

Presentation of ESSO Award

14:50

Presentation of selected abstract

15:00

Surgery for liver metastases: How far should the surgeon go?
Thomas Grüenberger, MD

15:20

The multimodal treatment of liver metastases: Frequently asked questions
Bernard Nordlinger, MD

15:40

Multidisciplinary management of peritoneal carcinomatosis from colorectal cancer: New perspectives
Marcello Deraco, MD

16:00

Liver directed therapy – When and how? (Selective radiotherapy, drug eluting beads or intrahepatic chemotherapy)
Volker Heinemann, MD, PhD

Session XXI: Report on expert discussion

16:20

Presentation of outcome of expert discussion on metastatic pancreatic cancer
Mario Dicato, MD and Eric Van Cutsem, MD, PhD

16:40

Adjourn